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Introduction
The prevalence of migraine in children between the age of
3 and 8 is about 3% and adolescents between 10%–19%
[1]. Migraine headaches can have adverse effects on the
lives of children and adolescent sufferers. These include
impaired school performance, poor attendance, and
diminished participation in extracurricular activities and
social life. All can adversely affect the growth and devel-
opment of adolescents [1, 2]. Despite the fact that
migraine is a real debilitating entity in this age group,
there is no Food and Drug Administration (FDA)-
approved abortive triptan therapy in migraine sufferers
under the age of 18. Therefore, there is a clear and impor-
tant need for studies to identify effective and well tolerat-
ed abortive triptan migraine-specific therapies in adoles-
cent migraine sufferers.
Several studies have been published in the use of trip-
tans in children and adolescents. Nasal sumatriptan has
been shown to be effective and safe in 5–12-year-old chil-
dren [3, 4]. Rizatriptan has been shown to be effective and
safe for the acute treatment of migraine in adolescents [5].
Although zolmitriptan was found to be similar to placebo
in efficacy, it was found to be well tolerated and safe in
adolescents [6]. Naratriptan efficacy and safety was stud-
ied in adolescents [7].
Recent medical analyses [8, 9] have shown that all oral
triptans at marketed doses are generally effective and well
tolerated. Rizatriptan, almotriptan and eletriptan provide
the highest likelihood of consistent success [8].
Almotriptan and naratriptan had lower rates of adverse
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Abstract The objective was to
investigate the safety and efficacy
of almotriptan in patients aged
11–17 years old with acute
migraine. Fifteen patients aged
11–17 with a history of migraine
with or without aura were treated
with almotriptan. Reduction in
headache severity, disability and
adverse effects were studied.
Almotriptan in doses ranging from
6.25 to 12.5 mg was well tolerated.
There were virtually no adverse
effects except for one case of tran-
sient mild stiffness. Of the 15
patients, only 2 demonstrated no
efficacy without adverse effects. In
the other 13 patients, not only was
almotriptan effective, but again, no
significant adverse effects were
reported. Almotriptan is probably
safe and effective in patients aged
11–17. This small open-label pilot
study should support the feasibility
of a large randomised controlled
study to demonstrate tolerability
and efficacy of almotriptan in chil-
dren and adolescents with episodic
migraine.
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events in comparison to other triptans [9]. In a single
study of eletriptan in adolescents, there was no statistical
difference between eletriptan and placebo treatment
groups [10]. As there are no formally published data or tri-
als in almotriptan usage under the age of 18, it seemed
reasonable to study its efficacy and safety in children and
adolescents suffering from episodic migraine attacks.
Patients and methods
Fifteen patients, 14 female and 1 male, presented with a history
of migraine with or without aura. Diagnosis was based on
International Headache Society (IHS) criteria. All patients had
normal brain imaging studies and no developmental, behaviour-
al or medical problems. With the exception of two patients <50
kg who were given 6.25 mg almotriptan, the other patients, who
weighed >50 kg, were administered 12.5 mg almotriptan.
Abortive treatment was offered only if the headache frequency
was no greater than 4 migraine attacks/month with a greater than
24-h headache-free interval in between attacks. Informed con-
sent was obtained from the guardians in the presence of the
patient. All guardians were told about the non-FDA indications
of all triptans including the references in the literature support-
ing triptan efficacy and safety in the abortive treatment of
migraine in patients aged less than 18 [3–7]. Severity of pain and
duration of the attacks were recorded. Efficacy in terms of per-
cent reduction of pain, speed of efficacy, ability to continue
school or social activity, and adverse effects were also recorded.
This study was performed in accordance with the ethical
standards of the 1964 Declaration of Helsinki.
Results
In all 15 patients, no serious adverse effects were report-
ed (Table 1). One patient described transient mild stiff-
ness that was not significant and did not impair school or
social performance. The efficacy of almotriptan was sat-
isfactory in this patient. In two patients, almotriptan was
ineffective but without any adverse effects. In the
remaining 13 responder patients, almotriptan resulted in
rapid onset of pain relief with no untoward effects.
Redosing in <24 h did not occur in any patients.
Headache frequency remained at <4 headache attacks
per month throughout the study period, which is contin-
uing after one year. All responders were able to continue
school and other activities without interruption during
almotriptan abortive treatment.
Conclusion
In this small almotriptan study, and in the rizatriptan,
nasal sumatriptan and zolmitriptan studies, efficacy, safe-
ty and tolerability were equivalent to those of adults. This
small pilot study revealed safety and tolerability of
almotriptan in all of the subjects. Our study also suggests
therapeutic efficacy for the acute treatment of migraine in
the young migraine sufferer under the age of 18. Although
this is a small open-label pilot study from which defini-
tive conclusions cannot be drawn, the significance of
Table 1 Patient profiles and treatment responses
Age Sex Migraine Dx Dosea (mg) Treatment resultsb Adverse effects
1. 11 F (Visual) aura 6.25 Severe to mild in 2 h, pain free in 3h None
2. 11 F Without aura 12.5 Pain free in 2 h None
3. 12 F Without aura 12.5 Severe to mild in 2 h, pain free in 4 h None
4. 12 F Without aura 12.5 Pain free in 2 h None
5. 13 F Without aura 6.25 Pain free in 2 h None
6. 14 F (Visual) aura 12.5 Pain free in 2 h None
7. 14 F Without aura 12.5 Pain free in 2 h None
8. 14 F (Visual) aura 12.5 Pain free in 2 h None
9. 15 M (Visual) aura 12.5 Severer to mild in 2 h, pain free in 3 h None
10. 15 F Without aura 12.5 Ineffective None
11. 16 F Without aura 12.5 Severe to mild in 2 h, pain free in 3 h Transient stiffness
12. 16 F Without aura 12.5 Severe to mild in 2 h, pain free in 4 h None
13. 16 F (Visual) aura 12.5 Ineffective None
14. 17 F Without aura 12.5 Pain free in 2 h None
15. 17 F (Visual aura) 12.5 Pain free in 2 h None
a6.25 mg was used if <50 kg, otherwise 12.5 mg
bNo patient required repeat dosing in <24 h; no patient required more than 4 doses/month. All responders were able to continue school and
other activities without interruption
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safety and efficacy of almotriptan offers an important
therapy in the suffering of these young migraineurs. The
adverse impact of migraine attacks in children and ado-
lescents is often underappreciated by parents, teachers
and even physicians. Devastating, repetitive migraine
attacks are too often not satisfactorily attenuated or abort-
ed by non-triptan therapies. They can lead to long-term
academic, social and behavioural consequences. Frequent
severe migraine attacks can result in central sensitisation,
predisposing the young migraineur to increased future
migraine episodes. In a recent study, the probability of
successful treatment with aspirin and metoclopramide
decreased as the severity of the headache-related disabil-
ity increased. Among the most disabled 25% of patients,
the attacks were controlled successfully with combination
aspirin and metoclopramide in only 26% of patients. In
patients with substantial disability, it is appropriate to pre-
scribe a triptan early in the course, which is in keeping
with a stratified approach to care [9].
This study suggests that almotriptan is safe and effec-
tive in the treatment of young patients with acute
migraine. A larger randomised placebo-controlled trial
using a larger number of subjects is necessary to firmly
establish the efficacy and safety of almotriptan in the
young migraineur. However, until these studies have been
completed, based upon our study, and the study of other
triptans in the literature, it seems reasonable to utilise
almotriptan abortive therapy in well selected patients who
suffer from acute, debilitating, migraine attacks in the
11–17-year-old age group.
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